Products

Extensive Product Profile: Understanding Canmab 440mg Injection Canmab 440mg Injection contains Trastuzumab, a highly sophisticated, targeted recombinant humanized IgG1 monoclonal antibody designed to combat specific overexpressing malignancies. Developed utilizing advanced recombinant DNA technology and manufactured to strict international quality benchmarks by Biocon Biologics, Canmab 440mg is a foundational multi-dose targeted therapeutic tool used globally to treat aggressive, biomarker-positive cancers. 1. Clinical Indications & Usage HER2-Overexpressing Breast Cancer: Metastatic Breast Cancer (MBC): Used as a first-line treatment in combination with taxanes (paclitaxel or docetaxel) for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, or as a single agent in patients who have progressed after one or more chemotherapy regimens for advanced disease. Early Breast Cancer (EBC): Indicated for the treatment of patients with HER2-positive early breast cancer following surgery, completion of standard chemotherapy, or integrated within adjuvant/neoadjuvant chemo-regimens to significantly minimize recurrence risks. 2. Mechanism of Action: How Canmab Works Selective HER2 Receptor Binding: Trastuzumab binds with high affinity to sub-domain IV of the extracellular domain of the HER2 protein. This interaction halts downstream intracellular signaling cascades (specifically the MAPK and PI3K/Akt pathways) that drive rapid, uncontrolled cell division and tumor survival. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC): By binding directly to the tumor surface, Canmab actively flags the cancer cell for destruction. This recruits host immune cells, such as Natural Killer (NK) cells, to selectively attack and eliminate the marked tumor cells while sparing normal tissues lacking HER2 overexpression. 3. Administration and Dosing Guide Administration Route: Canmab 440mg is supplied as a lyophilized sterile powder in a multi-dose vial. It must be reconstituted using the co-packed bacteriostatic solvent or Sterile Water for Injection (SWFI) and diluted into a 250 mL infusion bag of 0.9% Sodium Chloride Injection. It must be administered exclusively as an Intravenous (IV) Infusion. It must never be administered as an IV push, bolus, or subcutaneous injection. Standard Schedule: Dosing relies on a weight-based calculation ($mg/kg$) administered either on a weekly or a 3-weekly cycle, depending on the therapeutic indication. The initial loading dose is administered over 90 minutes, while subsequent maintenance infusions can be shortened to 30 minutes if well tolerated. ⚠️ Safety, Side Effects, and Monitoring Cardiotoxicity & Left Ventricular Dysfunction: Trastuzumab carries a significant risk of sub-clinical or clinical cardiac failure, presenting as a drop in Left Ventricular Ejection Fraction (LVEF) or Congestive Heart Failure (CHF) Echocardiograms or MUGA scans are mandatory at baseline, every 3 months during therapy, and periodically post-treatment. Risk escalates if administered alongside anthracycline-based chemotherapies. Common Side Effects: Fatigue, chills, mild diarrhea, nausea, headache, altered taste, fever, muscle/joint pain, runny nose, insomnia, and temporary reductions in blood cell counts (anemia, leukopenia). 📦 Storage and Handling Specifications Storage Environment: Store unopened vials of Canmab 440mg under continuous refrigeration between 2°C and 8°C (36°F to 46°F). Do not freeze the powder, reconstituted solutions, or diluent vials. Environmental Safeguards: Keep the vial sealed inside its original manufacturer box to shield the lyophilized cake from light and direct heat. Post-Reconstitution Integrity: When reconstituted with the provided bacteriostatic water containing preservative, the multi-dose solution remains stable for up to 28 days when stored under refrigeration at 2°C to 8°C. If reconstituted with unpreserved SWFI, it must be used immediately and any remaining portion discarded. Keep strictly out of reach of children. PRESCRIPTION MEDICINE IS: YES Why Choose Prime Care Impex? Verified Cold-Chain Integrity Authenticity Assured Efficient Customs Clearance [A Group of Prime Care Impex Pvt. Ltd.] 🌐Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Extensive Product Profile: Understanding Canmab 150mg Injection Canmab 150mg Injection contains Trastuzumab, an advanced, targeted recombinant humanized IgG1 monoclonal antibody designed to combat specific overexpressing malignancies. Developed via recombinant DNA technology and manufactured to stringent international quality benchmarks by Biocon Biologics, Canmab serves as a foundational therapeutic tool in targeted oncology, offering an essential pathway for managing aggressive, biomarker-positive cancers. 1. Clinical Indications & Usage HER2-Overexpressing Breast Cancer: Metastatic Breast Cancer (MBC): Used as a first-line treatment in combination with paclitaxel or docetaxel for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, or as a single agent in patients who have received one or more chemotherapy regimens for metastatic disease. Early Breast Cancer (EBC): Indicated for the treatment of patients with HER2-positive early breast cancer following surgery, completed standard chemotherapy, or in combination with adjuvant/neoadjuvant chemo-regimens to reduce recurrence risks. HER2-Positive Metastatic Gastric Cancer: Deployed in combination with cisplatin and fluorouracil (or capecitabine) for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior anti-cancer therapy for metastatic disease. 2. Mechanism of Action: How Canmab Works Selective HER2 Receptor Binding: Trastuzumab binds with high affinity to sub-domain IV of the extracellular domain of the HER2 protein. This prevents the activation of the receptor and halts downstream intracellular signaling cascades (like the MAPK and PI3K/Akt pathways) that drive rapid cell division and tumor growth. Inhibition of Extracellular Domain Cleavage: It suppresses the shedding or proteolytic cleavage of the HER2 extracellular domain, which would otherwise leave a highly active, uninhibited signaling remnant inside the cell membrane. 3. Administration and Dosing Guide Administration Route: Canmab 150mg is supplied as a lyophilized sterile powder in a single-dose vial. It must be reconstituted with Sterile Water for Injection (SWFI) and diluted into a 250 mL infusion bag of 0.9% Sodium Chloride Injection (USP). It must be administered exclusively as an Intravenous (IV) Infusion. It must never be administered as an IV push, bolus, or subcutaneous injection. Reconstitution Rule: Gently swirl the vial to aid dissolution. Do not shake, as excessive agitation can cause severe foaming and denature the structural integrity of the monoclonal antibody. ⚠️ Safety, Side Effects, and Monitoring Cardiotoxicity & Left Ventricular Dysfunction: Trastuzumab carries a significant risk of sub-clinical or clinical cardiac failure, presenting as a drop in Left Ventricular Ejection Fraction (LVEF) or Congestive Heart Failure (CHF). Echocardiograms or MUGA scans are mandatory at baseline, every 3 months during therapy, and periodically post-treatment. Risk escalates if administered alongside anthracycline-based chemotherapies. Pulmonary Toxicity: Severe respiratory events, including interstitial lung disease, pneumonitis, pleural effusion, and acute respiratory distress syndrome (ARDS), have been reported. It must be withheld or discontinued if significant respiratory impairment occurs. Common Side Effects: Fatigue, mild diarrhea, nausea, headache, altered taste, fever, muscle/joint pain, runny nose, sleep disturbances, and a temporary reduction in blood cell counts. 📦 Storage and Handling Specifications Storage Environment: Store unopened vials of Canmab 150mg under continuous refrigeration between 2°C and 8°C (36°F to 46°F). Do not freeze the powder or reconstituted solutions. Environmental Safeguards: Keep the vial sealed inside its original manufacturer box to shield the lyophilized cake from light and direct heat. PRESCRIPTION MEDICINE IS: YES Why Choose Prime Care Impex? Verified Cold-Chain Integrity Authenticity Assured Efficient Customs Clearance 📞 Contact PRIME CARE IMPEX — Pharmaceutical Exporter from India 🌐 Corporate Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Extensive Product Profile: Understanding Buselin 7ML Injection Buselin 7ML Injection contains Buserelin Acetate, a highly potent synthetic peptide analogue of the naturally occurring gonadotropin-releasing hormone (GnRH) or luteinizing hormone-releasing hormone (LH-RH). Manufactured to exacting international pharmaceutical quality benchmarks, this specialized hormonal therapy is globally integrated into clinical treatment regimens for hormone-dependent malignancies, reproductive disorders, and advanced fertility protocols. 1. Clinical Indications & Usage Advanced Prostate Cancer: Utilized as a foundational palliative treatment for adult patients with hormone-dependent advanced or metastatic carcinoma of the prostate gland. It functions as a medical alternative to surgical castration (orchiectomy) to slow tumor progression. Endometriosis Management: Prescribed to suppress ovarian hormone production, effectively reducing painful endometrial lesions, pelvic inflammation, and chronic pain symptoms in female patients. Assisted Reproductive Technology (ART): Integrated by fertility specialists into controlled ovarian hyperstimulation protocols (such as In Vitro Fertilization - IVF) to suppress premature, spontaneous luteinizing hormone (LH) surges, ensuring optimal timing for egg retrieval. 2. Mechanism of Action: How Buselin Works Initial Gonadotropin Stimulation (Flare Phase): Upon initial administration, Buserelin binds aggressively to GnRH receptors in the anterior pituitary gland, triggering a transient spike in the release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This temporarily raises testosterone in men and estradiol in women. Pituitary Down-Regulation: Continuous administration leads to the structural internalization and desensitization of these pituitary GnRH receptors (down-regulation). Hormonal Castration: Deprived of upstream signals, the pituitary gland stops producing LH and FSH. This halts hormone production at the source, plunging serum testosterone levels to castrate levels in men and serum estradiol levels to postmenopausal levels in women, starving hormone-responsive tumors and tissues of their growth drivers. 3. Administration and Dosing Guide Administration Route: Buselin 7ML is formulated for subcutaneous (SC) injection. It must be administered using a sterile technique into fatty tissue layers, typically alternating injection sites around the abdomen, thigh, or upper arm. It must never be given intravenously. Dosing Cadence: Dosing schedules are highly customized depending on the specific medical indication (e.g., daily subcutaneous injections for prostate cancer down-regulation vs. specific cyclic patterns in IVF protocols). Medical Oversight: Injection schedules, therapeutic monitoring, and clinical dosage titrations must be coordinated directly under the guidance of a prescribing endocrinologist, oncologist, or fertility specialist. ⚠️ Safety, Side Effects, and Monitoring Tumor Flare Symptoms: In prostate cancer patients, the temporary rise in testosterone during the first 1–2 weeks can cause a transient worsening of symptoms (e.g., bone pain, spinal cord compression, or urinary obstruction). Close monitoring and prophylactic anti-androgen therapies are frequently utilized during this initiation window. Common Side Effects: Hot flashes, excessive sweating, decreased libido, erectile dysfunction, mood swings, headaches, injection-site irritation (redness or swelling), breast tenderness, and vaginal dryness. 📦 Storage and Handling Specifications Environment: Store Buselin 7ML Injection under continuous refrigeration between 2°C and 8°C (36°F to 46°F). Do not freeze. Protection: Keep the multidose vial inside its original cardboard packaging to shield the solution from direct UV light and environmental heat exposure. Inspect the solution visually before administration; it must be completely clear and colorless without visible particulate matter. Keep strictly out of reach of children. PRESCRIPTION MEDICINE IS: YES Clinical Disclaimer: This profile is compiled strictly for educational research and medical evaluation. Buselin 7ML Injection is a specialized hormonal therapeutic agent available exclusively via valid clinical authorization. It must be administered and monitored solely under the direct guidance of a registered medical specialist. Why Choose Prime Care Impex? Verified Product Pedigree Efficient Border Clearance Specialized Cold-Chain Integrity 📞 Contact PRIME CARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Extensive Product Profile: Understanding Brukinsa 80mg Capsule Brukinsa 80mg Capsule contains Zanubrutinib, a highly potent, second-generation small-molecule inhibitor of Bruton's Tyrosine Kinase (BTK). Developed with enhanced kinase selectivity to minimize off-target side effects, Brukinsa is prescribed globally by hematologists and oncologists as a premier targeted treatment for diverse B-cell malignancies and blood cancers. 1. Clinical Indications & Usage Chronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL): Prescribed for adult patients with newly diagnosed or relapsed/refractory CLL or SLL as a highly effective baseline monotherapy. Mantle Cell Lymphoma (MCL): Indicated for the treatment of adult patients with aggressive mantle cell lymphoma who have received at least one prior systemic therapy. Waldenström’s Macroglobulinemia (WM): Deployed globally to suppress abnormal plasma-like B cells and control excessive IgM protein production in adult patients. Follicular Lymphoma (FL): Utilized in combination with obinutuzumab for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. 2. Mechanism of Action: How Brukinsa Works Targeted BTK Inactivation: Zanubrutinib forms a selective, irreversible covalent bond with the cysteine residue (Cys481) in the active site of the Bruton’s Tyrosine Kinase (BTK) enzyme. B-Cell Receptor Signaling Disruption: By locking down the BTK protein, Brukinsa completely halts downstream B-cell receptor (BCR) signal cascades, effectively cutting off communication lines through the NF-κB and MAPK pathways. Apoptosis Evocation: Without these essential survival and growth signals, malignant B cells stop multiplying, fail to migrate into protective lymphoid tissues, and are forced into programmed cell death (apoptosis). 3. Administration and Dosing Guide Administration Route: Brukinsa 80mg is administered orally. The capsules must be swallowed whole with a glass of water. They should never be opened, broFood Dynamics: Can be taken consistently with or without meals. ken, crushed, or dissolved. Standard Schedule: The standard recommended adult daily dose is 320 mg. This can be administered either as 320 mg once daily (four 80mg capsules) or split evenly as 160 mg twice daily (two 80mg capsules in the morning and two at night), roughly 12 hours apart. Dose Modifications: Treating oncologists may dynamically adjust or temporarily pause doses depending on hematological toxicity levels, development of side effects, or co-administration of strong CYP3A inhibitors. ⚠️ Safety, Side Effects, and Monitoring Hemorrhage Risk: Fatal and serious bleeding events can occur. Patients should monitor closely for signs of unusual bruising, blood in urine/stool, or severe headaches. Therapy may need to be withheld before and after scheduled surgical procedures. Cardiac Arrhythmias: Atrial fibrillation and atrial flutter have been reported. Regular cardiac assessments are required, especially for patients with pre-existing risk factors like high blood pressure or structural heart defects. Common Side Effects: Diarrhea, muscle pain, skin rashes, bruising, upper respiratory tract infections, coughing, fatigue, and low platelet counts. 📦 Storage and Handling Specifications Environment: Store Brukinsa 80mg capsules at room temperature, ideally below 30°C (86°F) in a dry environment. Safeguards: Keep the capsules inside their original manufacturer bottle or blister strip to protect the medicine from high humidity and direct UV light exposure. Keep strictly out of reach of children and domestic pets. PRESCRIPTION MEDICINE IS: YES Clinical Disclaimer: This profile is compiled strictly for educational research and immediate medical assessment. Brukinsa 80mg Capsule is an advanced oncology medication available exclusively via legal clinical authorization. It must be administered and supervised solely under the guidance of a qualified hematologist-oncologist. Why Choose Prime Care Impex? 100% Authentic Origins End-to-End Customs Efficiency Specialized Cold-Chain Integrity 📞 Contact PRIME CARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Corporate Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Learn about Alkeran Injection 50 mg, equivalent to Melphalan BP 50 mg injection with 10 ml solvent diluent. Explore uses, mechanism, administration guidance, safety, storage, regulatory documentation, and global availability through Primecare IMPEX. Alkeran Injection 50 mg – Melphalan BP Powder for Injection with 10 ml Solvent Diluent Alkeran Injection 50 mg contains Melphalan, an anti-cancer chemotherapy medicine used under specialist medical supervision. It is supplied as a powder for injection with a solvent diluent, commonly described as Melphalan BP 50 mg injection with 10 ml solvent diluent. Melphalan belongs to a class of medicines known as alkylating agents. It works by damaging the DNA of rapidly dividing cells, which helps slow or stop the growth of certain cancer cells. Official product information describes melphalan injection as a medicine used in cancer treatment settings such as multiple myeloma and ovarian cancer, depending on country-specific approval and physician decision. Attribute Information Product Name Alkeran Injection 50 mg Generic Name Melphalan Strength 50 mg Dosage Form Powder and solvent for solution for injection/infusion Composition Equivalent to Melphalan BP 50 mg with 10 ml solvent diluent Therapeutic Category Anti-cancer / Cytotoxic chemotherapy medicine Drug Class Alkylating agent Route Intravenous use only, as directed by oncology specialist Use Type Prescription-only cancer medicine Handling Cytotoxic medicine; requires trained medical handling Alkeran Injection 50 mg may be used in cancer treatment under the supervision of a qualified oncologist. Melphalan injection is commonly associated with the treatment of: Certain international product references mention melphalan injection at conventional intravenous dosage for ovarian cancer treatment. 2. Mechanism of Action: How Alkeran Injection Works Alkeran Injection contains Melphalan, which is a bifunctional alkylating agent. Its action is linked to DNA cross-linking. In simple terms, melphalan attaches to DNA inside cancer cells and interferes with cell replication. This can reduce the ability of cancer cells to multiply. Official pharmacology references describe melphalan as forming reactive intermediates that bind with DNA, especially at guanine sites, causing DNA cross-linking and preventing cell replication. Because it affects rapidly dividing cells, melphalan can also affect healthy cells such as bone marrow cells. That is why blood count monitoring and specialist supervision are essential. Why Choose Primecare IMPEX? Primecare IMPEX supports access to pharmaceutical products with a focus on proper product details, documentation support, and professional communication. Key Reasons Pharmaceutical exporter, supplier, and distributor from India Support for oncology and specialty medicine inquiries Product information with strength, pack, batch, and expiry details Documentation guidance based on destination requirements Professional packaging and shipment coordination Support for global locations including USA, UK, Saudi Arabia, Thailand, Australia, Singapore, and Jamaica Direct WhatsApp and email communication for quick product inquiry Contact Primecare IMPEX – Pharmaceutical Exporter from India Company: Primecare IMPEX Business Type: Exporter | Supplier | Distributor Website: www.medicineexporterfromindia.com Email: raakeshkashiwar@gmail.com WhatsApp: +91 9673008130 WhatsApp Link: https://wa.me/919673008130 Alkeran Injection exporter from India Melphalan injection exporter from India Alkeran Injection 50 mg global supply Melphalan BP injection international shipping Alkeran Injection supplier for overseas buyer Oncology medicine exporter India Cancer injection exporter from India Melphalan 50 mg IV injection Melphalan injection protocol information Alkeran Injection prescribing information Melphalan alkylating agent injection Melphalan injection multiple myeloma High-dose melphalan injection information Melphalan injection safety profile Where to find Alkeran Injection 50 mg Alkeran Injection 50 mg information Melphalan injection for cancer treatment Alkeran Injection price inquiry Alkeran Injection availability Melphalan injection with solvent diluent Alkeran chemotherapy injection details

Extensive Product Profile: Understanding Brcaone 150mg Tablet Brcaone 150mg Tablet contains Olaparib, an advanced, first-in-class selective Poly (ADP-ribose) Polymerase (PARP) inhibitor. Manufactured to the highest global pharmaceutical standards by Emcure Pharmaceuticals Ltd., this targeted oral antineoplastic agent is integrated into precision-guided oncology protocols worldwide to manage complex, biomarker-specific malignancies. 1. Clinical Indications & Usage Advanced Ovarian Cancer: Used as maintenance treatment for adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. gBRCAm HER2-Negative Metastatic Breast Cancer: Indicated for patients with germline BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Metastatic Pancreatic Cancer: Deployed as a first-line maintenance therapy for adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on a minimum of 16 weeks of a first-line platinum-based chemotherapy regimen. 2. Mechanism of Action: How Brcaone Works PARP Trapping: Brcaone physically traps the PARP enzymes at the site of single-strand DNA damage. This accumulation stalls moving replication forks during cellular division, transforming manageable single-strand breaks into lethal double-strand DNA breaks. PARP Enzyme Inhibition: Olaparib selectively blocks the enzymatic activity of PARP1 and PARP2, which are crucial for repairing single-strand DNA breaks via the Base Excision Repair pathway. 3. Administration and Dosing Guide Administration Route: Brcaone 150mg is an oral tablet formulation. It must be swallowed whole with a glass of water. Do not chew, crush, dissolve, or split the tablet, as this disrupts the controlled-release delivery matrix. Food Interactions: Tablets can be taken consistently either with or without food. Standard Schedule: The standard recommended adult dosage is 300mg (two 150mg tablets) taken orally twice daily, roughly 12 hours apart, bringing the total baseline daily dose to 600mg. Dose Modifications: Treating oncologists track individual hematological tolerance closely. Dose adjustments down to 250mg or 200mg twice daily may be carried out to manage treatment-emergent toxicities. ⚠️ Safety, Side Effects, and Monitoring Bone Marrow Suppression (Myelosuppression): Severe hematological toxicities, including severe anemia, neutropenia, and thrombocytopenia, are common. Baseline and monthly Complete Blood Counts CBC are mandatory. Treatment should be held if severe cytopenia develops. MDS/AML Risks: Rare but serious cases of Myelodysplastic Syndrome MDS or Acute Myeloid Leukemia AML—some fatal—have been reported in patients receiving PARP inhibitors. Patients must be monitored for prolonged cytopenias. Common Side Effects: Nausea, vomiting, severe fatigue, diarrhea, loss of appetite, changes in taste (dysgeusia), headache, dizziness, abdominal pain, indigestion (dyspepsia), and minor elevations in serum creatinine. 📦 Storage and Handling Specifications Storage Framework: Store Brcaone 150mg tablets below 30°C (86°F) in a dry, dark, climate-controlled zone. Environmental Safeguards: Keep the tablets sealed inside their original manufacturer bottle packaging. Protect the medication from high humidity, excess moisture, and direct UV light exposure. Keep strictly out of reach of children and domestic pets. 📄 Regulatory and Compliance Documentation Authentic Manufacturer Certificate of Analysis COA Verified Batch Origin Ledger and Packaging Tracking Data Global Import-Export Authorization & Custom Clearance PRESCRIPTION MEDICINE IS: YES Clinical Disclaimer: This profile is compiled strictly for international wholesale procurement, institutional distributors, and commercial research. Brcaone 150mg Tablet is an advanced oncology drug available exclusively under clinical authorization. It must be handled, dispensed, and utilized solely under the direct guidance of a registered oncology specialist Why Choose Primecare Impex? Full Batch Traceability Global Custom Specialists Validated Bulk Capacity 📞 Contact PRIMECARE IMPEX — Bulk Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Extensive Product Profile: Understanding Braunamide 25mg Capsule Braunamide 25mg Capsule contains Lenalidomide, a highly potent, small-molecule immunomodulatory drug possessing direct antineoplastic, anti-angiogenic, and microenvironmental-disrupting actions. Manufactured to rigorous international regulatory standards by Samarth Life Sciences Pvt. Ltd., this high-strength formulation is integrated globally into complex hematology-oncology treatment protocols to treat aggressive and advanced bone marrow and lymphatic malignancies. 1. Clinical Indications & Usage Multiple Myeloma (MM): Prescribed in combination with dexamethasone as a foundational therapy for adult patients with newly diagnosed multiple myeloma (who are eligible or ineligible for transplantation) or those with relapsed or refractory disease who have progressed following at least one prior anti-myeloma regimen. Mantle Cell Lymphoma (MCL): Authorized for the treatment of adult patients with relapsed or refractory mantle cell lymphoma whose disease has progressed following two prior systemic therapies, including at least one proteasome inhibitor (such as bortezomib). Follicular Lymphoma (FL) & Marginal Zone Lymphoma (MZL): Used in combination with a rituximab regimen for adult patients with previously treated Grade 1, 2, or 3a follicular lymphoma or marginal zone lymphoma. 2. Mechanism of Action: How Braunamide Works Direct Cytotoxicity: In malignant plasma lines, the immediate depletion of Ikaros and Aiolos downregulates key oncogenic drivers (like IRF4 and c-Myc), halting cell division and inducing rapid programmed cell death (apoptosis). Anti-Angiogenesis: Braunamide cuts off the tumor's microenvironmental support structure by blocking endothelial cell migration, effectively starving the tumor of the blood supply needed for growth. Targeted Transcription Factor Degradation: This structural binding alters the ligase's surface architecture, selectively forcing the recruitment, ubiquitination, and subsequent proteasomal destruction of two essential lymphoid transcription factors 3. Administration and Dosing Guide Administration Route: Braunamide 25mg is formulated strictly as an oral capsule. It must be swallowed whole with a full glass of water at roughly the same time each day. Never break, crush, chew, or open the capsule shell. Dosing Cycles: Dosing schedules are highly customized and cycle-dependent. A standard multiple myeloma regimen involves taking 25mg orally once daily on Days 1 through 21 of repeated 28-day cycles. Dose Modifications: Treating oncologists strictly monitor absolute neutrophil and platelet counts to manage necessary dose reductions, delays, or structural interruptions. ⚠️ Safety, Side Effects, and Monitoring Embryo-Fetal Toxicity (Black Box Warning): Lenalidomide is structurally related to thalidomide and possesses a severe risk of life-threatening human birth defects or embryo-fetal death. Strict Risk Evaluation and Mitigation Strategies or equivalent global controlled safety distribution frameworks apply Severe Myelosuppression: Can induce deep hematological toxicities, including severe neutropenia (low white blood cells) and thrombocytopenia (low platelets). Baseline and weekly Complete Blood Counts are mandatory during the first two cycles (8 weeks) of therapy. Common Side Effects: Severe fatigue, diarrhea, constipation, nausea, pruritus (severe skin itching), muscle cramps, cough, dyspnea (shortness of breath), peripheral edema, dizziness, and pyrexia. 📦 Storage and Handling Specifications Storage Parameters: Store Braunamide 25mg capsules below 30°C (86°F) in a dry, dark, climate-controlled zone. Safe Handling: Retain the capsules inside their original sealed blister cards until the exact moment of administration to shield them from environmental moisture and prevent accidental skin exposure to the internal powder. Keep strictly out of reach of children and domestic animals. 📄 Regulatory and Compliance Documentation Authentic Manufacturer Certificate of Analysis COA Verified Batch Origin Ledger and Tracking Data Global Import-Export Authorization & Custom Clearance PRESCRIPTION MEDICINE IS: YES Clinical Disclaimer: This profile is compiled strictly for international wholesale procurement, institutional distributors, and commercial research. Braunamide 25mg Capsule is a specialized oncology agent available strictly under clinical prescription and authorization.. Why Choose Primecare Impex? Full Batch Traceability Global Custom Specialists Validated Bulk Capacity 📞 Contact PRIMECARE IMPEX — Bulk Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Extensive Product Profile: Understanding Braunamide 10mg Capsule Braunamide 10mg Capsule contains Lenalidomide, an advanced, small-molecule immunomodulatory drug possessing potent anti-angiogenic and direct antineoplastic activities. Manufactured to international regulatory quality standards by Samarth Life Sciences Pvt. Ltd., it is integrated worldwide into complex oncology and hematology treatment protocols to combat aggressive bone marrow and lymphatic malignancies. 1. Clinical Indications & Usage Multiple Myeloma (MM): Prescribed in combination with dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma, or those with relapsed/refractory disease who have failed at least one prior anti-myeloma regimen. It is also deployed globally as a single-agent continuous maintenance therapy following autologous stem cell transplantation . Myelodysplastic Syndromes (MDS): Indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a cytogenetic deletion chromosomal abnormality, with or without additional cytogenetic alterations . Mantle Cell Lymphoma (MCL): Authorized for the treatment of adult patients with relapsed or refractory mantle cell lymphoma whose disease has relapsed or progressed following at least two prior systemic therapies, one of which must include a proteasome inhibitor like bortezomib. 2. Mechanism of Action: How Braunamide Works Ubiquitin Ligase Binding: Lenalidomide directly binds to cereblon an integral component of the functional cullin-RING E3 ubiquitin ligase enzyme complex. Anti-Angiogenesis: Braunamide blocks endothelial cell migration and microvessel formation, starving tumors of the blood supply and vital nutrients needed for expansion. Dual Anti-Tumor & Immunomodulatory Response: The deletion of Ikaros and Aiolos results in a direct down-regulation of oncogenic survival pathways, inducing rapid programmed cell death (apoptosis) in malignant plasma lines. 3. Administration and Dosing Guide Administration Route: Braunamide 10mg is formulated exclusively as an oral capsule. It must be swallowed whole with a glass of water at roughly the same time each day. Never break, crush, chew, or open the capsule shell. Food Dynamics: Capsules can be taken consistently either with or without food. Renal Adjustments: Because lenalidomide is primarily cleared by the kidneys, baseline renal function panels are mandatory, and down-titrations are required for patients experiencing moderate-to-severe renal impairment. ⚠️ Safety, Side Effects, and Monitoring Embryo-Fetal Toxicity: Lenalidomide is structurally related to thalidomide and possesses severe, life-threatening risks of human birth defects or embryo-fetal death. Strict Risk Evaluation and Mitigation Strategies or equivalent global safety distribution systems apply. Hematological Toxicities (Myelosuppression): Can cause severe neutropenia (low white blood cell counts) and thrombocytopenia (low platelet counts). Baseline and weekly Complete Blood Counts are required during the initial 8 weeks of treatment. Common Side Effects: Severe fatigue, diarrhea, constipation, nausea, pruritus (severe skin itching), muscle cramps, cough, breathlessness, peripheral edema, dizziness, and low-grade pyrexia. 📦 Storage and Handling Specifications Storage Parameters: Store Braunamide 10mg capsules below 30°C (86°F) in a dry, dark, climate-controlled zone. Safe Handling: Retain the capsules inside their original sealed blister packs until the exact moment of administration to protect them from environmental humidity and accidental structural damage. Keep strictly out of reach of children and domestic animals. 📄 Regulatory and Compliance Documentation Authentic Manufacturer Certificate of Analysis Verified Batch Origin Ledger and Tracking Data Global Import-Export Authorization & Custom Clearance PRESCRIPTION MEDICINE IS: YES Clinical Disclaimer: This profile is compiled strictly for international wholesale procurement, institutional distributors, and commercial research. Braunamide 10mg Capsule is a specialized oncology agent available strictly under clinical prescription and authorization. It must be dispensed, monitored, and adjusted solely under the direction of a registered hematology-oncology specialist. Why Choose Primecare Impex? Full Batch Traceability Global Custom Specialists Validated Bulk Capacity 📞 Contact PRIMECARE IMPEX — Bulk Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Extensive Product Profile: Understanding Bortrac 2mg Injection Bortrac 2mg Injection contains Bortezomib, an advanced, targeted antineoplastic agent belonging to the class of proteasome inhibitors. Manufactured in India by Glenmark Pharmaceuticals Ltd. to rigorous global quality benchmarks, it serves as a critical frontline and relapsed-therapy intervention in modern oncology protocols worldwide. 1. Clinical Indications & Usage Multiple Myeloma: Deployed as a foundational therapy, either as a standalone agent or in combination with other therapeutic regimens (such as dexamethasone, thalidomide, or pegylated liposomal doxorubicin). It is indicated for both newly diagnosed patients and those with progressive, relapsed, or refractory multiple myeloma. Mantle Cell Lymphoma (MCL): Indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy, or in combination configurations (e.g., with rituximab, cyclophosphamide, doxorubicin, and prednisone) for untreated disease when stem cell transplantation is not appropriate. 2. Mechanism of Action: How Bortrac Works 26S Proteasome Inhibition: Bortezomib reversibly inhibits the chymotrypsin-like activity of the 26S proteasome, a multi-subunit enzyme complex responsible for degrading damaged, misfolded, or unneeded regulatory proteins within cells. Targeted Apoptosis: The resulting cellular imbalance alters key downstream survival signaling networks, driving the malignant plasma or mantle cells into rapid, programmed cell death (apoptosis) while showing a preferential impact on highly proliferative tumor lines over stable healthy tissue. 3. Administration and Dosing Guide Administration Route: Bortrac 2mg is a lyophilized powder for reconstitution. It must be administered exclusively by a qualified medical professional via Subcutaneous (SC) injection or Intravenous (IV) bolus injection. Administration Warning: Strictly Forbid Intrathecal Administration. Inadvertent intrathecal injection is fatal. Dose Modifications: Treating oncologists closely track individual tolerance and hematological values to manage necessary delays, dose de-escalations, or transitions between IV and SC routes. 4. Safety, Side Effects, and Monitoring Peripheral Neuropathy: Treatment can cause or worsen treatment-emergent peripheral neuropathy (characterized by burning, tingling, numbness, or pain in hands and feet). SC administration reduces this risk compared to IV. Hematological Toxicity: Severe myelosuppression, including thrombocytopenia (low platelets), neutropenia (low white blood cells), and anemia, is common. Complete Blood Counts (CBC) must be checked prior to every single dose. Common Side Effects: Fatigue, nausea, diarrhea, vomiting, decreased appetite, constipation, headache, dizziness, insomnia, and mild injection-site reactions. Hypotension & Dehydration: Patients may experience orthostatic or postural hypotension. Caution is required in patients with pre-existing dehydration or those taking antihypertensive medications. 5. Storage and Handling Specifications Cold Chain Logistics: Store the unopened vial in a clinical refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze. Environmental Protection: Keep the vial stored in its original manufacturer carton to shield the compound from direct UV light exposure. Keep strictly out of reach of children and unauthorized personnel. 6. Regulatory, Compliance & Sourcing Documentation Authentic Certificate of Analysis (COA) Verified Batch Origin & Manufacturing Ledger Global Import/Export Clearance & Compliance Documentation PRESCRIPTION MEDICINE: YES Clinical Disclaimer: This profile is compiled exclusively for international wholesale procurement and commercial educational research. Bortrac 2mg Injection is available exclusively under direct clinical authorization. It must be handled, reconstituted, and administered solely by a registered oncology care team. Bortezomib is highly unsafe for use during pregnancy due to definitive risks of fetal toxicity. Why Choose Primecare Impex? Validated Cold Chain Integrity End-to-End Batch Traceability Global Compliance Support 📞 Contact PRIMECARE IMPEX — Bulk Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] Your trusted logistics partner and bulk pharmaceutical supplier. 🌐 Corporate Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Extensive Product Profile: Understanding Bortlieva 3.5mg Injection Bortlieva 3.5mg Injection contains Bortezomib, an advanced, targeted antineoplastic agent belonging to the class of proteasome inhibitors. Manufactured under stringent international quality controls by Allieva Pharma Private Limited, it is globally utilized by hematologists and oncologists as a foundational component in treating complex hematological malignancies. 1. Clinical Indications & Usage Multiple Myeloma (Previously Treated): Used as monotherapy or in combination with other anti-cancer agents (such as pegylated liposomal doxorubicin or dexamethasone) for adult patients who have relapsed after or failed to respond to at least one prior therapy, or for whom stem cell transplantation is ineligible. Newly Diagnosed Multiple Myeloma: Integrated alongside alkylating agents and corticosteroids (e.g., melphalan and prednisone) as a first-line therapy for patients who are not candidates for high-dose chemotherapy and bone marrow transplantation. Pre-Transplant Induction Therapy: Prescribed in combination regimens (such as with dexamethasone, thalidomide, or cyclophosphamide) to safely reduce tumor burden before high-dose chemotherapy and autologous stem cell rescue. 2. Mechanism of Action: How Bortlieva Works Reversible 26S Proteasome Inhibition: It selectively binds to and blocks the chymotrypsin-like activity of the 26S proteasome—the primary cellular enzyme complex responsible for breaking down damaged or misfolded proteins. Disruption of Homeostasis: By preventing targeted protein degradation, it causes an acute, toxic buildup of faulty intracellular proteins. This triggers an overwhelming endoplasmic reticulum stress response. 3. Administration and Dosing Guide Administration Route: Bortlieva 3.5mg must be administered exclusively by a registered oncology healthcare professional in a clinical or hospital setting. Self-administration is strictly prohibited. Modes of Delivery: It can be delivered either via Subcutaneous (SC) injection (under the skin, typically into the thigh or abdomen at a concentration of 2.5 mg/mL) or Intravenous (IV) injection (directly into a vein as a 3 to 5-second bolus at a concentration of 1 mg/mL). The SC route is often preferred to reduce the risk of peripheral nerve toxicities. ⚠️ Safety, Side Effects, and Monitoring Peripheral Neuropathy: May induce new or worsening nerve damage, presenting as tingling, burning sensations, numbness, or pain in the hands and feet. Hematological Toxicities: Frequent cycles can induce transient thrombocytopenia (low platelet count), neutropenia (low white cells), and anemia. Complete Blood Counts (CBC) must be checked before every single dose. Hypotension: Orthostatic/postural hypotension can occur. Caution must be exercised in patients with pre-existing dehydration or those taking anti-hypertensive medications. Common Side Effects: Nausea, vomiting, diarrhea, constipation, profound fatigue, pyrexia (fever), reduced appetite (anorexia), headache, and sleep disturbances. 📦 Storage and Handling Specifications Temperature Range: Store the unconstitutioned lyophilized powder vial below 30°C (86°F) in a dry, temperature-controlled facility. (Note: Certain institutional guidelines recommend refrigeration at 2°C to 8°C; check specific batch criteria upon receipt). Light Sensitivity: Keep the vial enclosed inside its original manufacturer box to shield the active chemical compound from direct light and UV exposure. 📄 Regulatory and Compliance Documentation Authentic Manufacturer Certificate of Analysis (COA) Verified Batch-Specific Ledger and Origin Documentation Global Drug Import-Export Compliance PRESCRIPTION MEDICINE IS: YES Clinical Disclaimer: This profile is compiled exclusively for international wholesale procurement, institutional buyers, and commercial distribution research. Bortlieva 3.5mg Injection is a specialized cytotoxic agent available exclusively under strict oncology authorization. It must be dispensed and administered solely under the direct guidance of a registered oncology specialist. Why Choose Primecare Impex? 100% Traceability Cross-Border Regulatory Support Secure Cold-Chain & Bulk Capacity 📞 Contact PRIMECARE IMPEX — Bulk Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] Your trusted logistics partner and bulk pharmaceutical supplier. 🌐 Corporate Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Extensive Product Profile: Understanding Bortlieva 2mg Injection Bortlieva 2mg Injection contains Bortezomib, an advanced, targeted antineoplastic agent belonging to the class of proteasome inhibitors. Manufactured under stringent international quality controls by Allieva Pharma Private Limited, it is globally utilized by hematologists and oncologists as a core component in treating complex hematological malignancies. 1. Clinical Indications & Usage Multiple Myeloma (Previously Treated): Used as monotherapy or in combination with other anti-cancer agents (such as pegylated liposomal doxorubicin or dexamethasone) for adult patients who have relapsed after or failed to respond to at least one prior therapy, or for whom stem cell transplantation is ineligible . Newly Diagnosed Multiple Myeloma: Integrated alongside alkylating agents and corticosteroids (e.g., melphalan and prednisone) as a first-line therapy for patients who are not candidates for high-dose chemotherapy and bone marrow transplantation. 2. Mechanism of Action: How Bortlieva Works Reversible 26S Proteasome Inhibition: It selectively binds to and blocks the chymotrypsin-like activity of the 26S proteasome—the primary cellular enzyme complex responsible for breaking down damaged or misfolded proteins. Disruption of Homeostasis: By preventing targeted protein degradation, it causes an acute, toxic buildup of faulty intracellular proteins. This triggers an overwhelming endoplasmic reticulum stress response. 3. Administration and Dosing Guide Administration Route: Bortlieva 2mg must be administered exclusively by a registered oncology healthcare professional in a clinical or hospital setting. Self-administration is strictly prohibited. Modes of Delivery: It can be delivered either via Subcutaneous (SC) injection (under the skin, typically into the thigh or abdomen) or Intravenous (IV) injection (directly into a vein as a 3 to 5-second bolus). The SC route is often preferred to reduce the risk of peripheral nerve toxicities. Dosing Schedule: Dosing cycles fluctuate widely depending on the underlying indication, patient body surface area and concurrent chemotherapy drugs. A typical cycle involves a twice-weekly regimen for 2 weeks followed by a rest period. Dose adjustments or delays are dynamically managed by the physician based on hematological and neurological tolerability. ⚠️ Safety, Side Effects, and Monitoring Peripheral Neuropathy: May induce new or worsening nerve damage, presenting as tingling, burning sensations, numbness, or pain in the hands and feet. Hematological Toxicities: Frequent cycles can induce transient thrombocytopenia (low platelet count), neutropenia (low white cells), and anemia. Complete Blood Counts (CBC) must be checked before every single dose. Cardiac and Hepatic Risks: Rare instances of congestive heart failure and acute liver enzyme elevations have been documented, requiring regular baseline and ongoing organ function panels. Common Side Effects: Nausea, vomiting, diarrhea, constipation, profound fatigue, pyrexia (fever), reduced appetite (anorexia), headache, and sleep disturbances. 📦 Storage and Handling Specifications Temperature Range: Store the unconstitutioned lyophilized powder vial below 25°C (77°F) in a dry, temperature-controlled facility. Light Sensitivity: Keep the vial enclosed inside its original manufacturer box to shield the active chemical compound from direct light and UV exposure. Reconstituted Solutions: Once mixed with normal saline, the solution should be administered immediately or handled strictly within institutional stability protocols. Keep entirely out of reach of children. 📄 Regulatory and Compliance Documentation Authentic Manufacturer Certificate of Analysis (COA) Verified Batch-Specific Ledger and Origin Documentation Global Drug Import-Export Compliance RESCRIPTION MEDICINE IS: YES Clinical Disclaimer: This profile is compiled exclusively for international wholesale procurement, institutional buyers, and commercial distribution research. Bortlieva 2mg Injection is a specialized cytotoxic agent available exclusively under strict oncology authorization. It must be dispensed and administered solely under the direct guidance of a registered oncology specialist. Why Choose Primecare Impex? 100% Traceability Cross-Border Regulatory Support Secure Cold-Chain & Bulk Capacity 📞 Contact PRIMECARE IMPEX — Bulk Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] Your trusted logistics partner and bulk pharmaceutical 🌐 Corporate Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

📄 Extensive Product Profile: Understanding Bortenat 3.5mg Injection Bortenat 3.5mg Injection contains Bortezomib (3.5 mg as a sterile lyophilized powder in a single-dose vial), an advanced, first-in-class selective proteasome inhibitor therapeutic agent. Manufactured to rigorous global pharmaceutical standards by Natco Pharma Ltd., this specialized parenteral oncology medication is prescribed by hematologists and oncologists worldwide to manage complex plasma cell and lymphatic system malignancies. 1. Clinical Indications & Usage Multiple Myeloma (Newly Diagnosed): Indicated as part of multi-agent combination regimens (frequently alongside melphalan and prednisone or dexamethasone/thalidomide) for the treatment of adult patients with previously untreated multiple myeloma who are ineligible for high-dose chemotherapy and blood stem cell transplantation. Multiple Myeloma (Relapsed/Refractory): Deployed as monotherapy or in synergistic combination with pegylated liposomal doxorubicin or dexamethasone for patients with progressive multiple myeloma who have received at least one prior clinical treatment. 2. Mechanism of Action: How Bortenat Works 26S Proteasome Inhibition: It functions as a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome inside mammalian cells. The 26S proteasome is a massive protein complex responsible for degrading damaged or misfolded proteins. Disruption of Homeostasis: By blocking this enzymatic garbage disposal mechanism, Bortenat prevents the targeted degradation of pro-apoptotic proteins and cell-cycle regulators. This leads to an excessive, toxic accumulation of polyubiquitinated proteins within the cell. Targeted Synthetic Lethality: This accumulation disrupts multiple intracellular signaling cascades, down-regulates Nuclear Factor Kappa B (NF-κB) activation, triggers heavy endoplasmic reticulum stress, and directly drives hyper-proliferating malignant cells into programmed cell death (apoptosis) while relatively sparing non-cancerous tissue. 3. Administration and Dosing Guide Administration Route: Intravenous (IV) bolus injection (over 3 to 5 seconds) or Subcutaneous (SC) injection. Bortenat 3.5mg must be reconstituted and administered exclusively by trained medical professionals within an oncology day-care or clinical hospital infrastructure. It is highly unsafe for intrathecal administration. Stability Framework: Following reconstitution with sterile 0.9% Sodium Chloride, the solution should be inspected visually for particulate matter and discoloration prior to delivery. ⚠️ Safety, Side Effects, and Monitoring Peripheral Neuropathy: Treatment can cause severe peripheral neuropathy (primarily sensory, though motor neuropathy has been reported). Patients must be closely monitored for symptoms of burning pain, tingling, numbness, or weakness in the hands and feet. Dose adjustments or route changes (switching from IV to SC) may be managed by the specialist. Hematological Toxicities: Transient thrombocytopenia (low platelet counts) and neutropenia (low white blood cell counts) are common, characteristically cyclical in nature. Baseline and regular Complete Blood Counts (CBC) must be performed during every cycle of therapy. Common Side Effects: Nausea, diarrhea, vomiting, severe fatigue, pyrexia (fever), loss of appetite (anorexia), constipation, headache, dizziness, and localized injection site reactions. 📦 Storage and Handling Specifications (Bortenat 3.5mg) Storage Framework: Store the un-reconstituted Bortenat 3.5mg dry-vial package below 25°C (77°F) in a controlled climate environment. Environmental Safeguards: Keep the single-dose vial sealed within its original manufacturer outer carton. Protect completely from high humidity, excessive moisture, and direct UV light exposure. Follow standard institutional cytostatic hazardous medication handling and disposal procedures. Keep strictly out of reach of children and domestic animals. 📄 Regulatory and Compliance Documentation Authentic Certificate of Analysis (COA) Verified Batch Origin Ledger & GMP Tracking Protocols Global Import/Export Compliance and Customs Documentation PRESCRIPTION MEDICINE IS: YES Clinical Disclaimer: This profile is compiled strictly for international wholesale procurement, commercial pharmaceutical trade evaluation, and institutional research. Bortenat 3.5mg Injection is a specialized oncology agent available exclusively under valid clinical authorization (PRESCRIPTION MEDICINE IS YES). 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [GROUP OF PRIME CARE IMPEX PVT. LTD.] Your Trusted Pharmaceutical Exporter, Bulk Supplier, and Global Distributor from India. 🌐 Corporate Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130